Huaota Biopharma and Almirall Enter Global Collaboration and Licensing Agreement for a Novel Monoclonal Antibody Targeting Dermatological Diseases

3Month27On [date], Huaota announced that it has reached an agreement withAlmirall on aEarly StageMonoclonal Antibody Candidate DrugAchieveGlobal Research Collaboration and Licensing Agreement to Develop Monoclonal Antibody Candidates for New Targets with Multiple Potential Indications, Including Medical Dermatology.

According to the agreement, Huaota has the rights to develop and commercialize projects and products in China.AlmirallHas the rights to global development and commercialization projects and products outside of China. By leveraging an innovative R&D platform, Huaota will carry out relevant research until obtaining molecules with clinical proof-of-concept.AlmirallWill pay Huaota a total amount3.4Hundreds of millions of dollars in upfront payments, development and commercialization milestone payments, as well as corresponding tiered royalties.

HuaotaCEODr. Zhu Xiangyang stated: This collaboration highlights Huaota as a rising force in the research and development of large-molecule antibody drugs.PlatformThe FrontierInnovationAndTransformation CapabilityHighly recognized by international partners, paving the way for more...International Cooperation in the Initiation of Innovative Projects,The external authorization of self-developed projects has created open, pragmatic, and forward-looking conditions. Both parties will subsequently adhere to the principles of win-win cooperation and enhanced synergy.Risk Sharing,The Spirit of Benefit Sharing to Realize the Global Commercial Value of Cooperative Projects in This Field。

Huaota will continue to actively and steadily advance the strategic decision of product out-licensing or cooperation, in order to accelerate the expansion of the international market and achieve strategic upgrading and value transformation.

About Almirall (Almirall）

AlmirallIs a global pharmaceutical company focused on medical dermatology. It closely collaborates with leading scientists, healthcare professionals, and patients, adhering to the mission of improving patients' lives by helping them achieve their aspirations and dreams for healthy living. Standing at the forefront of science, the company is committed to delivering breakthrough and differentiated innovative therapies in medical dermatology to meet patient needs.AlmirallFounded in1944Year, headquartered in Barcelona, and publicly listed on the Spanish Stock Exchange (Stock Code:ALM）。2025The total annual revenue reached11.145Million euros, with more than2100Person.Almirallproducts improve patients' lives every day and have currently expanded globally100Launched in multiple countries.

AboutHuaota

HuaHuaota BiopharmaceuticalSystemHuahai Pharmaceutical(600521.SH)The subsidiary is a biopharmaceutical R&D company that focuses on independent research and development with a global perspective, specializing in areas such as oncology and autoimmune diseases. The company was founded in2013Year, located in Zhangjiang, Shanghai, has currently advanced12Clinical research of the project, including those already in the new drug application stage (NDA) The first domestically developed drug in China for the treatment of generalized pustular psoriasisIL-36RMonoclonal Antibody; Entered Pivotal Clinical StageIIIUsed for the treatment of non-small cell lung cancer and endometrial cancer.PD-L1/VEGFBispecific antibody; and entering clinical trialsIThe world's first innovative treatment for multiple indications, including moderate to severe asthma, during the periodTSLP/IL-11Dual Antibody and Treatment of Pyogenic Hidradenitis, etc.IL-17A/IL-36RBispecific antibody.

Copyright © 2026 PHARMCUBE. All Rights Reserved. Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. Medicine Cube assumes no responsibility for any loss incurred by any party due to the use of the content herein.